Short blinatumomab to clear leftover B-ALL cells
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests if a shorter course of blinatumomab can remove minimal residual disease (MRD) — tiny traces of leukemia not seen under a microscope — in people with B-cell acute lymphoblastic leukemia after initial treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia (a certain type of leukemia).
- After treatment, tests show very small amounts of leukemia left (called MRD).
- You are well enough to be active (ECOG score 0-2).
- You do not have significant organ damage.
- You have a potential stem cell donor (related or unrelated).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a subcutaneous (under the skin) form of blinatumomab for people with B-cell acute lymphoblastic leukemia who are in remission but still have tiny amounts of leukemia cells that can be detected by sensitive tests. The goal is to see if this treatment is safe and can get rid of those remaining cells.
This trial tests whether a drug called blinatumomab can clear leftover leukemia cells in children with B-cell acute lymphoblastic leukemia (B-ALL) who still have traces of disease after standard treatment. It aims to reduce the chance of relapse.
This trial tests a drug called blinatumomab for people with B-ALL whose leukemia has come back at a very low level (detected only by sensitive testing) after a stem cell transplant. The goal is to see if blinatumomab can clear these remaining leukemia cells and prevent a full relapse.
This trial tests a lower dose of chemotherapy followed by 14 days of blinatumomab for adults newly diagnosed with a type of leukemia called B-ALL. The goal is to see if this approach works well and reduces side effects.
This trial tests a short course of blinatumomab (a targeted immunotherapy) given before a stem cell transplant in people with low amounts of B-ALL leukemia. The goal is to prepare the body for transplant and improve outcomes.
This trial tests blinatumomab, an immune therapy, in young people with B-cell acute lymphoblastic leukemia (B-ALL) after their transplant or when they are getting ready for transplant. The goal is to lower the chance of the leukemia coming back by targeting remaining leukemia cells.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.